Evotec SE

NasdaqGS:EVO Stock Report

Market Cap: US$1.6b

Evotec Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Christian Wojczewski

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1.7yrs
Board average tenure3yrs

Recent management updates

Recent updates

Evotec: Weak Performance, But Long-Term Potential Is There

Aug 30

Evotec: Still A Speculative Buy After A Significant Decline

Apr 24

Amgen joins TIAP, Evotec at innovation hub for forming life science companies

Oct 17

Evotec stock dips despite US DoD contract up to $49.9M to develop antibody for plague

Sep 20

Evotec to acquire Central Glass Germany to bolster drug substance manufacturing

Aug 25

Evotec stock falls amid pact with Alpine for commercial process for potential lupus drug ALPN-303

Aug 10

Boehringer, Evotec, bioMérieux form joint venture Aurobac to combat antimicrobial resistance

Jul 06

CEO

Christian Wojczewski (52 yo)

less than a year

Tenure

Dr. Christian Wojczewski serves as Chief Executive Officer of Evotec SE since July 01, 2024. He holds a diploma and a doctorate in chemistry from the Johann Wolfgang Goethe University in Frankfurt am Main....

Leadership Team

NamePositionTenureCompensationOwnership
Laetitia Rouxel
CFO & Member of Management Board1.7yrs€890.00k0.029%
$ 452.7k
Cord Dohrmann
Chief Scientific Officer & Member of Management Board14.3yrs€1.48m0.11%
$ 1.7m
Craig Johnstone
COO & Member of Management Board5.9yrs€1.18m0.011%
$ 176.7k
Christian Wojczewski
Chief Executive Officerless than a yearno datano data
Aurelie Dalbiez
Chief People Officer & Member of Management Boardless than a yearno datano data
Volker Braun
Executive VP and Head of Global Investor Relations & ESGno datano datano data
Christian Dargel
EVP Global Head of Legal & Complianceno datano datano data
Gabriele Hansen
Senior VP & Head of Global Corporate Communications & Marketingno datano datano data
Ian Hunneyball
Senior Vice President of Programme Management & Clinical Operationsno data€116.00kno data
David Hallet
Executive Vice Presidentno datano datano data
Uwe Andag
EVP Head of Metabolic Diseasesno datano datano data
Christiane Honisch
SVP Head of Diagnosticsno datano datano data

1.7yrs

Average Tenure

53yo

Average Age

Experienced Management: EVO's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Roland Sackers
Independent Vice Chairperson of the Supervisory Board5.5yrs€95.00kno data
Iris Loew-Friedrich
Independent Chairperson of the Supervisory Board10.5yrs€150.00kno data
Duncan McHale
Member of the Supervisory Boardless than a yearno datano data
Camilla Languille
Member of the Supervisory Board2.5yrs€60.00kno data
Constanze Ulmer-Eilfort
Independent Member of Supervisory Board3.5yrs€85.00kno data
Wesley Wheeler
Independent Supervisory Boardless than a yearno datano data

3.0yrs

Average Tenure

58yo

Average Age

Experienced Board: EVO's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 00:02
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Evotec SE is covered by 35 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Laura Lopez PinedaBaader Helvea Equity Research
Gerhard SchwarzBaader Helvea Equity Research